Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence
- 827 Downloads
To review vascularized-pigment epithelial detachment (V-PED) treatment visual outcome, and to assess acute retinal pigment epithelium (RPE) tear incidence.
One hundred and thirty-two eyes of 125 consecutive patients with age-related macular degeneration and V-PED were included. Ninety-four eyes (71.2%) were associated with choroidal new vessels (CNV), 38 (28.8%) with retinal angiomatous proliferation (RAP). Patients, treated over a 10-year period with the time-current therapy, received: verteporfin photodynamic therapy (PDT) (group 1, 38 eyes), combined intravitreal triamcinolone acetonide (IVTA) and PDT (group 2, 44 eyes) or intravitreal anti-VEGF injection (bevacizumab or ranibizumab) (group 3, 50 eyes).
Mean follow-up was 20.5 months. At month 12, all eyes treated with PDT or with IVTA and PDT showed a mean significant severe visual decrease. Eyes with CNV lost −0.67 and −0.37 logMAR (p < 0.01 and p < 0.01 respectively), and eyes with RAP −0.55 and −0.31 logMAR (p < 0.01 and p = 0.01 respectively). RPE tear occurred in 14 eyes (36.8%) and in six eyes (13.6%) in groups 1 and 2 respectively. Eyes treated with anti-VEGF therapy showed slight mean visual acuity decrease at month 12. Those with CNV had a mean baseline best-corrected visual acuity (BCVA) of 0.36 ± 0.24 logMAR, final of 0.44 ± 0.30 logMAR (−0.08 logMAR, n.s.). In eyes with RAP, mean baseline BCVA was 0.58 ± 0.39 logMAR, final was 0.78 ± 0.47 logMAR (−0.20 logMAR, n.s.). RPE tear occurred in 14 eyes (36.8%). Patients with either V-PED with CNV or a better baseline BCVA showed greater risk of acute RPE tear (p = 0.01 and p = 0.003 respectively).
Effective treatment for vascularized PED is still lacking. Until now, only stabilization of the disease has been achieved using anti-VEGF therapy, but the risk of RPE tear can further hamper our expectations. Baseline characteristics are helpful for prognosis, but patients must be informed of the uncertain response. New therapeutic strategies are needed.
KeywordsAge-related macular degeneration Retinal pigment epithelial detachment Choroidal neovascularization Retinal angiomatous proliferation RPE tear antiVEGF
The Authors wish to thank Michael John of the Vita-Salute San Raffaele University for the English language editing of this manuscript.
Conflict of interest
Ugo Introini: none. Ana Torres Gimeno: none. Fabrizio Scotti: none. Marco Setaccioli: none. Silvia Giatsidis: none. Francesco Bandello: Novartis Pharmaceuticals Corporation; Allergan, Inc.; Alcon, Inc.; Bayer Schering Pharma; Farmila-THEA; Genentech, Inc.; Pfizer, Inc.; Bausch & Lomb.
- 3.Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, Quentel G, Paliès S, Sanchez A, De Gendre AS, Schluep H, Weber M, Delcourt C (2007) Types of choroidal neovascularization in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173–1176PubMedCrossRefGoogle Scholar
- 7.Axer-Siegel R, Ehrlich R, Avisar I, Kramer M, Rosenblatt I, Priel E, Weinberger D (2006) Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 37:455–461PubMedGoogle Scholar
- 26.Golbaz I, Ahlers C, Stock G, Schütze C, Schriefl S, Schlanitz F, Simader C, Prünte C, Schimdt-Erfurth U (2011) Quantification of the therapeutic response of intraretinal, subretinal and subpigmentepithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 52:1599–1605PubMedCrossRefGoogle Scholar
- 29.Nicolò M, Ghiglione D, Calabria G (2006) Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalnol 16:770–773Google Scholar